Bovine serum albumin-based nanoparticles containing resveratrol: Characterization and antioxidant activity

Journal of Drug Delivery Science and Technology

Volumn 39, Issue , 2017, Pages 147-155

  Fonseca, Dyenefer Pereira ^a   Khalil, Najeh Maissar ^a   Mainardes, Rubiana Mara ^a  

^a UNIVERSIDADE ESTADUAL DO CENTRO OESTE   (Brazil)

Author keywords

Antioxidant; Bovine serum albumin; HOCl; Nanoparticles; Resveratrol

Indexed keywords

BOVINE SERUM ALBUMIN; BOVINE SERUM ALBUMIN BASED NANOPARTICLE; HYPOCHLOROUS ACID; NANOCARRIER; RESVERATROL; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; IN VITRO STUDY; NANOANALYSIS; NANOENCAPSULATION; NANOPHARMACEUTICS; OXIDATIVE STRESS; PARTICLE SIZE; REFRIGERATION; ROOM TEMPERATURE; ZETA POTENTIAL;

EID: 85016433417     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jddst.2017.03.017     Document Type: Article

References (54)

1. [1] Halliwell, B., Free radicals, antioxidants, and human disease: curiosity, cause, or consequence?. Lancet 344 (1994), 721–724, 10.1016/S0140-6736(94)92211-X.
2. [2] Ames, B.N., Shigenaga, M.K., Hagen, T.M., Oxidants, antioxidants, and the degenerative diseases of aging. Proc. Natl. Acad. Sci. U. S. A. 90 (1993), 7915–7922, 10.1073/pnas.90.17.7915.
3. [3] Witztum, J.L., The oxidation hypothesis of atherosclerosis. Lancet 344 (1994), 793–795.
4. [4] Stahl, V., Sies, H., Antioxidant defense: vitamins E and C and carotenoids. Diabetes 46 (1997), S14–S18.
5. [5] Langcake, P., Pryce, R.J., The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury. Physiol. Plant Pathol. 9 (1976), 77–86, 10.1016/0048-4059(76)90077-1.
6. [6] Hung, L.M., Chen, J.K., Huang, S.S., Lee, R.S., Su, M.J., Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc. Res. 47 (2000), 549–555, 10.1016/S0008-6363(00)00102-4.
7. [7] Goldberg, D., Yan, J., Ng, E., Diamandis, E., Karumanchiri, A., Soleas, G., Waterhouse, A., A global survey of trans- resveratrol concentrations in commercial wines. Am. J. Enol. Vitic. 46 (1995), 159–165.
8. [8] Anekonda, T.S., Resveratrol-A boon for treating Alzheimer's disease?. Brain Res. Rev. 52 (2006), 316–326, 10.1016/j.brainresrev.2006.04.004.
9. [9] Martinez, J., Moreno, J.J., Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem. Pharmacol. 59 (2000), 865–870, 10.1016/S0006-2952(99)00380-9.
10. [10]] Asensi, M., Medina, I., Ortega, A., Carretero, J., Ba??o, M.C., Obrador, E., Estrela, J.M., Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic. Biol. Med. 33 (2002), 387–398, 10.1016/S0891-5849(02)00911-5.
11. [11] Colin, D., Lancon, A., Delmas, D., Lizard, G., Abrossinow, J., Kahn, E., Jannin, B., Latruffe, N., Antiproliferative activities of resveratrol and related compounds in human hepatocyte derived HepG2 cells are associated with biochemical cell disturbance revealed by fluorescence analyses. Biochimie, 90(n.d.), 1674–84, 10.1016/j.biochi.2008.06.006.
12. [12] Nakagawa, H., Kiyozuka, Y., Uemura, Y., Senzaki, H., Shikata, N., Hioki, K., Tsubura, A., Resveratrol inhibits human breast cancer cell growth and may mitigate the effect of linoleic acid, a potent breast cancer cell stimulator. J. Cancer Res. Clin. Oncol. 127 (2001), 258–264.
13. [13] Harwood, M., Danielewska-Nikiel, B., Borzelleca, J.F., Flamm, G.W., Williams, G.M., Lines, T.C., A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem. Toxicol. 45 (2007), 2179–2205, 10.1016/j.fct.2007.05.015.
14. [14] Walle, T., Hsieh, F., DeLegge, M.H., Oatis, J.E., Walle, U.K., High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 32 (2004), 1377–1382, 10.1124/dmd.104.000885.
15. [15] Wenzel, E., Somoza, V., Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res. 49 (2005), 472–481, 10.1002/mnfr.200500010.
16. [16] Williamson, G., Manach, C., Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am. J. Clin. Nutr., 81, 2005 doi:81/1/230S [pii].
17. [17] Mainardes, R.M., Gremião, M.P.D., Brunetti, I.L., Da Luiz Fonseca, M., Khalil, N.M., Zidovudine-loaded PLA and PLA-PEG blend nanoparticles: influence of polymer type on phagocytic uptake by polymorphonuclear cells. J. Pharm. Sci. 98 (2009), 257–267, 10.1002/jps.21406.
18. [18] Klaypradit, W., Huang, Y.W., Fish oil encapsulation with chitosan using ultrasonic atomizer. LWT - Food Sci. Technol. 41 (2008), 1133–1139, 10.1016/j.lwt.2007.06.014.
19. [19] Kipp, J.E., The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int. J. Pharm. 284 (2004), 109–122, 10.1016/j.ijpharm.2004.07.019.
20. [20] Kumari, A., Yadav, S.K., Yadav, S.C., Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B Biointerfaces 75 (2010), 1–18, 10.1016/j.colsurfb.2009.09.001.
21. [21] Pujara, N., Jambhrunkar, S., Wong, K.Y., McGuckin, M., Popat, A., Enhanced colloidal stability, solubility and rapid dissolution of resveratrol by nanocomplexation with soy protein isolate. J. Colloid Interface Sci. 488 (2017), 303–308, 10.1016/j.jcis.2016.11.015.
22. [22] Hao, J., Zhao, J., Zhang, S., Tong, T., Zhuang, Q., Jin, K., Chen, W., Tang, H., Fabrication of an ionic-sensitive in situ gel loaded with resveratrol nanosuspensions intended for direct nose-to-brain delivery. Colloids Surf. B Biointerfaces 147 (2016), 376–386, 10.1016/j.colsurfb.2016.08.011.
23. [23] Summerlin, N., Soo, E., Thakur, S., Qu, Z., Jambhrunkar, S., Popat, A., Resveratrol nanoformulations: challenges and opportunities. Int. J. Pharm. 479 (2015), 282–290, 10.1016/j.ijpharm.2015.01.003.
24. [24] Summerlin, N., Qu, Z., Pujara, N., Sheng, Y., Jambhrunkar, S., McGuckin, M., Popat, A., Colloidal mesoporous silica nanoparticles enhance the biological activity of resveratrol. Colloids Surf. B Biointerfaces 144 (2016), 1–7, 10.1016/j.colsurfb.2016.03.076.
25. [25] Soo, E., Thakur, S., Qu, Z., Jambhrunkar, S., Parekh, H.S., Popat, A., Enhancing delivery and cytotoxicity of resveratrol through a dual nanoencapsulation approach. J. Colloid Interface Sci. 462 (2016), 368–374, 10.1016/j.jcis.2015.10.022.
26. [26] da Rocha Lindner, G., Santos, D.B., Colle, D., Moreira, E.L.G., Prediger, R.D., Farina, M., Khalil, N.M., Mainardes, R.M., Improved neuroprotective effects of resveratrol-loaded polysorbate 80-coated poly(lactide) nanoparticles in MPTP-induced Parkinsonism. Nanomedicine 10 (2015), 1127–1138, 10.2217/nnm.14.165.
27. [27] Antonio, E., Khalil, N.M., Mainardes, R.M., Bovine serum albumin nanoparticles containing quercetin: characterization and antioxidant activity. J. Nanosci. Nanotechnol. 16 (2016), 1346–1353.
28. [28] Casa, D.M., Karam, T.K., De Cristo, A., Alves, S., Zgoda, A.A., Khalil, N.M., Mainardes, R.M., Bovine serum albumin nanoparticles containing Amphotericin B: characterization, cytotoxicity and in vitro antifungal evaluation. J. Nanosci. Nanotechnol. 15 (2015), 10183–10188, 10.1166/jnn.2015.11694.
29. [29] Sahoo, S.K., Parveen, S., Panda, J.J., The present and future of nanotechnology in human health care. Nanomedicine 3 (2007), 20–31, 10.1016/j.nano.2006.11.008.
30. [30] Parveen, S., Misra, R., Sahoo, S.K., Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine Nanotechnol. Biol. Med. 8 (2012), 147–166, 10.1016/j.nano.2011.05.016.
31. [31] Merodio, M., Arnedo, A., Renedo, M.J., Irache, J.M., Ganciclovir-loaded albumin nanoparticles: characterization and in vitro release properties. Eur. J. Pharm. Sci. 12 (2000), 251–259, 10.1016/S0928-0987(00)00169-X.
32. [32] Da Rocha Lindner, G., Khalil, N.M., Mainardes, R.M., Resveratrol-loaded polymeric nanoparticles: validation of an HPLC-PDA method to determine the drug entrapment and evaluation of its antioxidant activity. Sci. World J., 2013, 2013, 10.1155/2013/506083.
33. [33] Casa, D.M., Carraro, T.C.M.M., de Camargo, L.E.A., Dalmolin, L.F., Khalil, N.M., Mainardes, R.M., Poly(L-lactide) nanoparticles reduce amphotericin B cytotoxicity and maintain its in vitro antifungal activity. J. Nanosci. Nanotechnol. 15 (2015), 848–854, 10.1166/jnn.2014.9177.
34. [34] Paino, I.M., Ximenes, V.F., Fonseca, L.M., Kanegae, M.P., Khalil, N.M., Brunetti, I.L., Effect of therapeutic plasma concentrations of non-steroidal anti-inflammatory drugs on the production of reactive oxygen species by activated rat neutrophils. Braz J. Med. Biol. Res. 38 (2005), 543–551 doi:S0100-879X2005000400007 [pii]∖r/S0100-879X2005000400007.
35. [35] Gupta B, R., Kompella B, U., 1 edition Nanopaticles Technology for Delivery (Drugs and the Pharmaceutical Sciences), vol. 159, 2006, CRC Press, New York January 13, 2006.
36. [36] Avadi, M.R., Sadeghi, A.M.M., Mohammadpour, N., Abedin, S., Atyabi, F., Dinarvand, R., Rafiee-Tehrani, M., Preparation and characterization of insulin nanoparticles using chitosan and Arabic gum with ionic gelation method. Nanomedicine Nanotechnol. Biol. Med., 6, 2010, 10.1016/j.nano.2009.04.007.
37. [37] Jun, J.Y., Nguyen, H.H., Paik, S.Y.R., Chun, H.S., Kang, B.C., Ko, S., Preparation of size-controlled bovine serum albumin (BSA) nanoparticles by a modified desolvation method. Food Chem. 127 (2011), 1892–1898, 10.1016/j.foodchem.2011.02.040.
38. [38] Yang, R., Shim, W.-S., Cui, F.-D., Cheng, G., Han, X., Jin, Q.-R., Kim, D.-D., Chung, S.-J., Shim, C.-K., Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor. Int. J. Pharm. 371 (2009), 142–147, 10.1016/j.ijpharm.2008.12.007.
39. [39] Li, J.L., Zu, Y.G., Zhao, X.H., Zhao, D.M., Chen, X.Q., An, Z.G., Wang, K.L., Preparation, characterization, and in vitro evaluation of resveratrol-loaded bovine serum album nanoparticles. Adv. Mater. Res. 345 (2011), 349–354, 10.4028/www.scientific.net/AMR.345.349.
40. [40] Guo, L., Yao, L., Sui, J., Preparation and effects of resveratrol bovine serum albumin nanoparticles on proliferation of human ovarian carcinoma cell SKOV3. Chem. J. Chin. Univ. 30 (2009), 474–477.
41. [41] Riekes, M.K., Barboza, F.M., Vecchia, D.D., Bohatch, M., Farago, P.V., Fernandes, D., Silva, M.A.S., Stulzer, H.K., Evaluation of oral carvedilol microparticles prepared by simple emulsion technique using poly(3-hydroxybutyrate-co-3-hydroxyvalerate) and polycaprolactone as polymers. Mater. Sci. Eng. C 31 (2011), 962–968, 10.1016/j.msec.2011.02.017.
42. [42] Trollope, L., Cruickshank, D.L., Noonan, T., Bourne, S.A., Sorrenti, M., Catenacci, L., Caira, M.R., Inclusion of trans -resveratrol in methylated cyclodextrins: synthesis and solid-state structures. Beilstein J. Org. Chem. 10 (2014), 3136–3151, 10.3762/bjoc.10.331.
43. [43] Kim, S., Ng, W.K., Dong, Y., Das, S., Tan, R.B.H., Preparation and physicochemical characterization of trans-resveratrol nanoparticles by temperature-controlled antisolvent precipitation. J. Food Eng. 108 (2012), 37–42, 10.1016/j.jfoodeng.2011.07.034.
44. [44] Liang, L., Tajmir-Riahi, H.A., Subirade, M., Interaction of beta-lactoglobulin with resveratrol and its biological implications. Biomacromolecules 9 (2008), 50–56, 10.1021/bm700728k.
45. [45] Sulkowska, A., Interaction of drugs with bovine and human serum albumin. J. Mol. Struct, 2002, 227–232, 10.1016/S0022-2860(02)00256-9.
46. [46] Holmberg, K., Jönsson, B., Kronberg, B., Lindman, B., Solution and Polymers in Aqueous Solution. 2002, 10.1002/0470856424.
47. [47] Li, X., Li, H., Liu, M., Li, G., Li, L., Sun, D., From guest to ligand – a study on the competing interactions of antitumor drug resveratrol with β-cyclodextrin and bovine serum albumin. Thermochim. Acta 521 (2011), 74–79, 10.1016/j.tca.2011.04.007.
48. [48] Xiao, J.B., Chen, X.Q., Jiang, X.Y., Hilczer, M., Tachiya, M., Probing the interaction of trans-resveratrol with bovine serum albumin: a fluorescence quenching study with tachiya model. J. Fluoresc, 2008, 671–678, 10.1007/s10895-008-0346-x.
49. [49] Huang, X., Brazel, C.S., On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J. Control. Release 73 (2001), 121–136, 10.1016/S0168-3659(01)00248-6.
50. [50] Thote, A.J., Chappell, J.T., Gupta, R.B., Kumar, R., Reduction in the initial-burst release by surface crosslinking of PLGA microparticles containing hydrophilic or hydrophobic drugs. Drug Dev. Ind. Pharm. 31 (2005), 43–57, 10.1081/DDC-200043985.
51. [51] Görner, T., Gref, R., Michenot, D., Sommer, F., Tran, M.N., Dellacherie, E., Lidocaine-loaded biodegradable nanospheres. I. Optimization of the drug incorporation into the polymer matrix. J. Control. Release 57 (1999), 259–268, 10.1016/S0168-3659(98)00121-7.
52. [52] Siepmann, J., Peppas, N.A., Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv. Drug Deliv. Rev. 48 (2001), 139–157, 10.1016/S0169-409X(01)00112-0.
53. [53] Cha, M.K., Kim, I.H., Glutathione-linked thiol peroxidase activity of human serum albumin: a possible antioxidant role of serum albumin in blood plasma. Biochem. Biophys. Res. Commun. 222 (1996), 619–625, 10.1006/bbrc.1996.0793.
54. [54] Zgliczyński, J.M., Stelmaszyńska, T., Domański, J., Ostrowski, W., Chloramines as intermediates of oxidation reaction of amino acids by myeloperoxidase. Biochim. Biophys. Acta - Enzymol. 235 (1971), 419–424, 10.1016/0005-2744(71)90281-6.